Peripheral Neuritis Treatment Market Study Explores Industry Growth Toward $2.44 Billion

The peripheral neuritis treatment market is on a promising growth trajectory, driven by continuous innovations and increased adoption of diverse therapeutic approaches. As awareness about peripheral neuritis rises and treatment options expand, this sector is poised for sustained development throughout the coming years. Here is a detailed overview of the market size, key players, emerging trends, and segment classifications shaping the future of peripheral neuritis care.

Overview of Peripheral Neuritis Treatment Market Size and Forecast Through 2030
The peripheral neuritis treatment market is predicted to steadily expand, reaching a valuation of $2.44 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 4.8%. Several factors contribute to this upward trend, including progress in drug therapies and greater use of non-pharmacological treatments such as transcutaneous electrical nerve stimulation (TENS) and acupuncture. Additionally, the growing presence of online and retail pharmacies, increased emphasis on lifestyle and diet management, and the extension of diabetic care initiatives and specialized clinics all play significant roles. Anticipated market trends involve a rise in AI-powered peripheral neuritis monitoring tools, wider integration of digital health platforms for managing peripheral neuropathy, advancements in genomic and precision medicine, adoption of IoT-enabled patient monitoring devices, and the development of smart manufacturing processes for peripheral neuritis therapeutics.

The peripheral neuritis treatment market size has grown strongly in recent years. It will grow from $1.93 billion in 2025 to $2.03 billion in 2026 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to high prevalence of diabetic neuropathy, limited availability of targeted therapies, reliance on conventional analgesics and anticonvulsants, growing awareness of peripheral neuritis symptoms, fragmented healthcare infrastructure.

Download a free sample of the peripheral neuritis treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21254&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Players Leading the Peripheral Neuritis Treatment Arena
The landscape of the peripheral neuritis treatment market is dominated by several renowned pharmaceutical companies. These include Pfizer Inc., Johnson & Johnson (J&J), AstraZeneca Plc, Novartis AG, GSK plc, Takeda Pharmaceuticals & Co. Ltd., Eli Lilly and Co., Mallinckrodt Pharmaceuticals plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr Reddys Laboratories Ltd., Cipla Inc., Amneal Pharmaceuticals LLC, Lupin Ltd., Daiichi Sankyo Co. Ltd., Glenmark Pharmaceuticals Ltd., and Cadila Pharmaceuticals Ltd.

Collaborative Efforts Advancing Peripheral Neuritis Therapies
In October 2024, Alkem Laboratories Limited, an Indian pharmaceutical firm, entered into a partnership with US-based Sonnet BioTherapeutics. Their collaboration focuses on the development, production, and commercialization of Sonnet's drug candidate SON-080, aimed at treating diabetic peripheral neuropathy (DPN) in India. Sonnet specializes in biotechnology with an emphasis on oncology, bringing its innovation expertise to this peripheral neuritis initiative.

View the full peripheral neuritis treatment market report:
https://www.thebusinessresearchcompany.com/report/peripheral-neuritis-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovative Treatments Driving Market Growth in Peripheral Neuritis
A notable trend within the peripheral neuritis treatment field is the emphasis on cutting-edge therapies such as magnetic peripheral nerve stimulation (mPNS). This non-invasive neuromodulation method uses magnetic fields to stimulate peripheral nerves, which helps alleviate pain, supports nerve regeneration, and improves motor function, particularly in neuropathy and musculoskeletal conditions. For instance, in January 2024, Neuralace Medical Inc., a US medical device manufacturer, announced FDA approval for Axon Therapy (mPNS) targeting chronic painful diabetic neuropathy (PDN). This therapy offers a rapid, painless, and non-invasive way to relieve pain. Clinical studies showed responder rates of 72.3% at 30 days and 81.4% at 90 days, demonstrating its significant effectiveness in decreasing pain and numbness while providing an alternative to conventional medications without their side effects.

How the Peripheral Neuritis Treatment Market is Categorized
This report segments the peripheral neuritis treatment market into the following categories:
1) Treatment Type: Pharmacological Therapies and Non-Pharmacological Therapies
2) Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Drug Stores
3) Applications: Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Other Applications

Within these main categories, further subsegments include:
- Pharmacological Therapies: Pain Relievers (Analgesics), Antidepressants, Anticonvulsants, and Topical Medications
- Non-Pharmacological Therapies: Physical Therapy, TENS, Acupuncture, as well as Lifestyle and Dietary Modifications

This structured segmentation helps to clearly map out the diverse approaches used in treating peripheral neuritis and supports targeted strategies for market expansion.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.